Skip to main content

Glenmark Pharmaceuticals receives ANDA approval for Desonide Ointment, 0.05%

 

Clinical courses

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Desonide Ointment, 0.05%, the generic version of Desonide Ointment, 0.05%, of Perrigo New York Inc.

According to IMS Health sales data for the 12 month period ending July 2017, the Desonide Ointment, 0.05% market  achieved annual sales of approximately $23.4 million*.

 

Glenmark's current portfolio consists of 124 products authorized for distribution in the U.S. marketplace and 62 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email